Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation (2014 - 2026)

Viridian Therapeutics, Inc.\DE's Share-based Compensation history runs 13 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 31.02% year-over-year to $13.4 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 228.44% increase from a year earlier, with the FY2023 full-year figure at $67.2 million, changed N/A from the prior year.
• Share-based Compensation grew to $13.4 million in Q1 2026 per VRDN's latest filing, from -$729000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $61.5 million in Q4 2023 and bottomed at -$33.2 million in Q4 2024.
• The 5-year median for Share-based Compensation is $10.2 million (2025), against an average of $4.7 million.
• Across the five-year window, Share-based Compensation soared 524.37% in 2023 and sank 333.2% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at -$14.5 million in 2022, then surged by 524.37% to $61.5 million in 2023, then sank by 153.96% to -$33.2 million in 2024, then surged by 97.8% to -$729000.0 in 2025, then soared by 1936.76% to $13.4 million in 2026.
• Per Business Quant, the three latest VRDN Share-based Compensation figures stand at $13.4 million (Q1 2026), -$729000.0 (Q4 2025), and -$20.3 million (Q3 2025).